Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/117775

In Collections

This item can be found in the following collections:

Iakoubova, O.A.; Robertson, M.; Tong, C.H.; Rowland, C.M.; Catanese, J.J.; Blauw, G.J.; ... ; Shepherd, J. (2010)

KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study

Article / Letter to editor
Background Statin therapy has been found to substantially and significantly reduce coronary events in carriers of the KIF6 719Arg variant (rs20455) but not in noncarriers. We investigated whether, among the elderly, statin therapy also significantly reduced coronary events in carriers but not in noncarriers. Design and methods Among 5752 patients of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) study, we assessed the effect of pravastatin, compared with placebo, on coronary events according to 719Arg carrier status using proportional hazards models. Results Since benefit from statin therapy in elderly patients has been primarily shown among those with prior vascular disease, we performed analyses in PROSPER patients with prior disease and found that pravastatin therapy significantly reduced events in 719Arg carriers [hazards ratio (HR): 0.66, 95% confidence interval (CI): 0.52-0.86] but not in noncarriers (HR: 0.94, 95% CI: 0.69-1.28), P = 0.09 for...Show moreBackground Statin therapy has been found to substantially and significantly reduce coronary events in carriers of the KIF6 719Arg variant (rs20455) but not in noncarriers. We investigated whether, among the elderly, statin therapy also significantly reduced coronary events in carriers but not in noncarriers. Design and methods Among 5752 patients of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) study, we assessed the effect of pravastatin, compared with placebo, on coronary events according to 719Arg carrier status using proportional hazards models. Results Since benefit from statin therapy in elderly patients has been primarily shown among those with prior vascular disease, we performed analyses in PROSPER patients with prior disease and found that pravastatin therapy significantly reduced events in 719Arg carriers [hazards ratio (HR): 0.66, 95% confidence interval (CI): 0.52-0.86] but not in noncarriers (HR: 0.94, 95% CI: 0.69-1.28), P = 0.09 for interaction between treatment and carrier status. Among those without prior disease, no significant benefit was observed in either carriers or noncarriers. Among those with prior vascular disease in the placebo arm, Trp719Arg heterozygotes were at significantly greater risk, compared with noncarriers (HR: 1.36, 95% CI: 1.03-1.81, P = 0.03); the HR of 719Arg carriers, compared with noncarriers, was 1.28 (95% CI: 0.98-1.69, P = 0.07). Conclusion Elderly carriers of the KIF6 719Arg variant with prior vascular disease received significant benefit from pravastatin therapy; no benefit was observed in noncarriers with prior disease or in those without prior disease (carriers or noncarriers). Eur J Cardiovasc Prev Rehabil 17:455-461 (C) 2010 The European Society of CardiologyShow less
coronary heart disease the elderly genetic polymorphism prevention risk factors statin therapy coronary-heart-disease myocardial-infarction gene variants kinesin association prevention health trial risk
All authors
Iakoubova, O.A.; Robertson, M.; Tong, C.H.; Rowland, C.M.; Catanese, J.J.; Blauw, G.J.; Jukema, J.W.; Murphy, M.B.; Devlin, J.J.; Ford, I.; Shepherd, J.
Date
2010-08-31
Journal
European Journal of Cardiovascular Prevention and Rehabilitation
Volume
17
Issue
4
Pages
455 - 461
DOI
doi:10.1097/HJR.0b013e328336a0dd